Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

168P - Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC

Date

07 Dec 2023

Session

Poster Display

Presenters

CATERINA DE ROSA

Citation

Annals of Oncology (2023) 20 (suppl_1): 100621-100621. 10.1016/iotech/iotech100621

Authors

C. DE ROSA1, C. Tuccillo1, L. Amato2, F. Ciardiello1, V. Nardone1, F. Morgillo2, C.M. Della Corte1

Author affiliations

  • 1 Universita degli Studi della Campania Luigi Vanvitelli, Napoli/IT
  • 2 Universita degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 168P

Background

In the past decade, radiotherapy (RT) has been widely practised for treating extensive-stage small cell lung cancer (ES-SCLC). Despite this, it has been discouraged in phase III trials of first line chemoimmunotherapy. Instead, robust rationales have emerged in favour of using RT as a booster to promote a sustained anti-tumour immune response. On basis of published data defining a subtype of SCLC patients who respond to chemotherapy (CT) classified as \"inflamed\" and expressing high innate immune genes such as the STimulator of INterferon pathway (STING) pathway and based on further preclinical data supporting STING levels as potential biomarkers of response to combined chemo- and immunotherapy, we hypothesised that innate immune activation may provide an opportunity to evaluate anti-tumour immune activity in vitro.

Methods

We explored the landscape of STING, Mitochondrial antiviral-signaling protein (MAVS), Gamma-interferon-inducible protein (IFI-16) and immune-related cytokines expression both at mRNA and protein expression levels among two SCLC cell lines, namely H82 and H524. We then tested the effect of in vivo treatment with CT and RT (4 Gy dose) on PBMC subpopulations derived from SCLC patients by LDH cytotoxicity assay.

Results

We performed sequential in vitro treatment with CT and RT (4 Gy) in selected SCLC cell lines and we investigated changes in STING pathway, as indicator of DNA damage induced by CT and RT. cGAS, STING and downstream protein p-TBK1 and p-IRF3 were upregulated by CT plus RT in both cell lines. Interestingly, these increments were accompanied by high levels of DNA damage, as suggested by increased levels of H2A.X, ATM, ATR, and DNA-PK. IFI-16 DNA sensor was also increased at both protein and mRNA levels. Moreover, inflammatory T cells recruiting the chemokines IL6, IFN-β, CXCL5, CXCL10, were also significantly increased by sequential treatment with CT and RT. The SCLC patients-derived immune cells activity patients were also significantly increased post-RT as measured by LDH cytotoxicity assay.

Conclusions

We demonstrated in cellular models of SCLC a positive modulation of innate immune pathways with CT and RT sequential treatment, suggesting a possible boost role of RT in SCLC patients treated with chemoimmunotherapy.

Legal entity responsible for the study

The authors.

Funding

AIRC.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.